Related Experiment Video
Updated: Sep 15, 2025
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Effective blood glucose control in Chinese children with type 1 diabetes via a do-it-yourself artificial pancreas
Lihong Yang1,2, Fei Xie3, Linqi Han4
1Paediatrics, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Insights
The do-it-yourself artificial pancreas system (DIYAPS) significantly improves blood glucose control in Chinese children with type 1 diabetes (T1D). This advanced technology enhances time in range and reduces glucose levels safely.
Area of Science:
- Endocrinology
- Biomedical Engineering
- Pediatric Diabetes Management
Background:
- Artificial pancreas systems represent advanced blood glucose management tools.
- These systems are known to improve key glycemic control metrics like HbA1c and time in range.
- Previous reports on artificial pancreas use in Chinese children with type 1 diabetes (T1D) are lacking.
Purpose of the Study:
- To evaluate the safety and efficacy of do-it-yourself artificial pancreas systems (DIYAPS) in Chinese children with T1D.
- To assess the impact of DIYAPS on glycemic control parameters, specifically HbA1c and time in range (TIR).
Main Methods:
- A retrospective study was conducted on 41 children (ages 3-18) with T1D using a DIYAPS for at least three months.
- Inclusion criteria included T1D diagnosis, insulin pump use, and continuous glucose monitoring data.
- Primary outcomes measured were changes in HbA1c and TIR before and after DIYAPS implementation.
Main Results:
- DIYAPS use led to a significant increase in TIR (72.4% to 80.8%, p<0.01) and a decrease in time above range (TAR) (16.0% to 8.8%, p<0.01).
- Fasting blood glucose and HbA1c levels also decreased significantly (p<0.01 and p<0.05, respectively).
- No adverse events such as diabetic ketoacidosis or severe hypoglycemia were reported.
Conclusions:
- The do-it-yourself artificial pancreas system (DIYAPS) is a safe and effective intervention for Chinese children with T1D.
- DIYAPS demonstrated particular efficacy in improving time in range (TIR) for this pediatric population.
Background/Purpose:
The artificial pancreas system is among the most advanced devices for blood glucose management and is known to improve patients' glycated hemoglobin levels and time spent within the target glucose range. However, the use of an artificial pancreas in children with type 1 diabetes (T1D) in China has not yet been reported.
Methods:
A retrospective study was conducted involving patients diagnosed with T1D who used a do-it-yourself artificial pancreas system (DIYAPS). The main inclusion criteria were as follows: T1D diagnosis, age between 3 and 18 years, usage of an insulin pump, and continuous glucose monitoring records for at least 3 months. The exclusion criterion was any comorbid conditions that could interfere with the study. The primary outcomes measured were changes in hemoglobin A1c (HbA1c) and time in range (TIR) before and after the DIYAPS was used.
Results:
A total of 41 people were included in the study, including 21 males and 20 females, with a mean age of 9.4 years (standard deviation: 2.9 years), a median duration of T1D of 1.5 years (1.1-2.3), and a median duration of insulin pump use of 1.1 years (0.8-1.7). Compared with the baseline period (pre-DIYAPS), after using a DIYAPS, the TIR increased from 72.4% (57.9-82.4) to 80.8% (73.6-87.5; p < 0.01), the TAR (>10 mmol/L) decreased from 16.0% (8.2-21.2) to 8.8% (5.2-14.4; p < 0.01), the fasting blood glucose decreased from 8.2 mmol/L (7.2-9.4) to 6.7 mmol/L (6.3-7.6; p < 0.01), and the HbA1c decreased from 6.6% (6.1-7.6) to 6.3% (5.9-6.9; p < 0.05). No diabetic ketoacidosis, severe hypoglycemia, or other adverse events occurred during the use of the DIYAPS.
Conclusion:
DIYAPS is safe and effective in Chinese children with T1D, particularly in improving TIR.
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...